Advertisement
YOU ARE HERE: LAT HomeCollectionsSandoz Pharmaceuticals Corp
IN THE NEWS

Sandoz Pharmaceuticals Corp

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
December 18, 1996 | Times Staff and Wire Reports
The Federal Trade Commission conditionally approved the merger of Swiss drug giants Ciba-Geigy and Sandoz, a deal that would create the world's second-largest drug company, Novartis. The agency said it would require a record $1-billion-plus in divestitures and licensing to preserve competition in key areas. The agreement seeks to ensure a strong second player in the new field of gene therapy, a market the U.S. government estimates will mushroom to $45 billion by 2010.
Advertisement
BUSINESS
March 23, 1994 | From Times Staff and Wire Reports
Sandoz to Cut Anti-Cholesterol Drug Price: The company's move to sell its new medication for as much as 50% less than competing drugs pushed drug stocks lower on fears of a price war. East Hanover, N.J.-based Sandoz Pharmaceuticals Corp. will sell a month's supply of the newly approved drug, called Lescol, to wholesalers for $30.60. Stock prices of Merck & Co. and Bristol-Myers Squibb Co., which market rival anti-cholesterol drugs, fell.
BUSINESS
October 16, 1996 | Times Staff and Wire Reports
Sandoz to Buy Azupharma: The Swiss drug maker said it agreed to buy Germany's third-largest generic drug company for $416 million from drug wholesaler Gehe of Germany. The acquisition will help boost Sandoz's generic drug business--the stated aim of the man who will head Novartis Inc., the Swiss pharmaceutical company to be formed from the merger of Sandoz and Ciba-Geigy. Germany is the second-largest generics market in the world.
BUSINESS
September 4, 1992 | From Times Staff and Wire Reports
Drug Maker Sets Up Suit Settlement Fund: Sandoz Pharmaceuticals Corp., in a settlement of an antitrust lawsuit filed by all 50 states and the District of Columbia over its schizophrenia drug Clozaril, said it will provide $16 million in credits to about 10,000 patients who used the breakthrough drug from Feb. 5, 1990, to May 31, 1991. That period reflects the time when the company controlled the distribution and price of the drug. Sandoz now allows competitive distribution of Clozaril.
NEWS
September 1, 1989 | MARLENE CIMONS, Times Staff Writer
Federal officials are investigating Bolar Pharmaceutical Co. for possible fraud in connection with the approval of a generic version of the brand-name anti-depressant drug Mellaril. Knowledgeable officials said Thursday that both the Food and Drug Administration and the House Energy and Commerce oversight subcommittee are looking into charges that Bolar fraudulently submitted the brand-name drug instead of the generic version to a testing laboratory--the second such incident reported.
BUSINESS
August 19, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Sandoz Pharmaceuticals said Thursday that it will stop selling its Parlodel drug for the purpose of suppressing lactose in women who have just given birth. Used widely for treating symptoms of Parkinson's disease and various endocrine disorders, Parlodel had been blamed in consumer lawsuits for fatal strokes and seizures in women who took it after giving birth.
BUSINESS
May 4, 1996 | Times Staff and Wire Reports
EU Panel to Probe Ciba-Geigy/Sandoz Merger: The European Commission said it would launch a detailed investigation into the competitive aspects of the merger, which would create the world's second-largest drug company. The move is a sign the commission might impose conditions on the combination of the two Swiss chemical companies. The new company, to be called Novartis, would be the world's biggest supplier of crop-protection products and No. 2 in pharmaceuticals.
NEWS
March 8, 1996 | DAVID R. OLMOS, TIMES STAFF WRITER
Two Swiss drug rivals have agreed to a $27-billion merger that would create a global powerhouse in pharmaceuticals and chemicals and form one of the largest corporate marriages in history. The merger of Ciba-Geigy Ltd. and Sandoz Ltd., announced Thursday by the companies' Basel headquarters, would form the world's second-largest drug company, behind Britain's Glaxo-Wellcome, itself the product of a 1995 merger.
BUSINESS
March 8, 1996 | CHRIS KRAUL, TIMES STAFF WRITER
Sandoz Ltd. and Ciba-Geigy Ltd. have already shown a keen interest in buying pieces of biotechnology companies, particularly in California. Their planned $27-billion merger should enable them to invest even more, at the same time spurring other drug giants to pursue further mega-mergers themselves, analysts said Thursday.
BUSINESS
August 19, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Sandoz Pharmaceuticals said Thursday that it will stop selling its Parlodel drug for the purpose of suppressing lactose in women who have just given birth. Used widely for treating symptoms of Parkinson's disease and various endocrine disorders, Parlodel had been blamed in consumer lawsuits for fatal strokes and seizures in women who took it after giving birth.
BUSINESS
June 18, 1993 | ROBERT A. ROSENBLATT, TIMES STAFF WRITER
The federal government, angered by the Scripps Research Institute's proposed marketing agreement with a giant Swiss pharmaceutical company, is threatening to take away from Scripps the exclusive rights to patents from its biotechnology discoveries, the director of the National Institutes of Health told Congress on Thursday. In unusually strong language, Dr.
BUSINESS
March 22, 1993 | CHRIS KRAUL, TIMES STAFF WRITER
When Scripps Research Institute signed a 10-year, $300-million research agreement in December that gives Swiss pharmaceutical giant Sandoz first rights on all technology developed at the La Jolla facility, neither party anticipated the firestorm that was to erupt. Scripps seemed to be in line with other research laboratories--whether university-run or private--that have increasingly collaborated with the corporate world to make up for growing costs and a scarcity of government funding.
Los Angeles Times Articles
|